Furuyama Wakako, Takada Ayato
Hokkaido University Research Center for Zoonosis Control.
Uirusu. 2016;66(1):63-72. doi: 10.2222/jsv.66.63.
Ebolaviruses, members of the family Filoviridae, cause severe hemorrhagic fever in humans and nonhuman primates, with human case fatality rates of up to 90%. No effective prophylaxis or treatment for Ebola virus disease (EVD) is yet commercially available. During the latest outbreak of EVD in West Africa, several unapproved drugs were used for the treatment of patients. This outbreak has indeed accelerated efforts to develop antiviral strategies and some of the vaccine and drug candidates have undergone clinical trials. This article reviews previous researches and recent advances on the development of vaccine, therapeutics, and diagnostics for EVD.
埃博拉病毒是丝状病毒科的成员，可导致人类和非人类灵长类动物患上严重出血热，人类病死率高达90%。目前尚无针对埃博拉病毒病（EVD）的有效预防或治疗方法可供商业使用。在西非最近一次埃博拉病毒病疫情爆发期间，几种未经批准的药物被用于治疗患者。这次疫情确实加速了抗病毒策略的研发，一些候选疫苗和药物已经进入临床试验阶段。本文综述了此前关于埃博拉病毒病疫苗、治疗方法和诊断技术研发的研究及最新进展。
